Amarin Reports Third Quarter 2020 Financial Results and Provides Business Update
The Pharma Data
NOVEMBER 4, 2020
Expanded m edical society recommendations in support of the efficacy and safety of VASCEPA : The European Society of Cardiology expanded their guidelines to recommend use of VASCEPA in treating acute coronary syndrome patients. In addition, Amarin recognized licensing and royalty revenue of approximately $1.3 million and $8.9
40 
Let's personalize your content